• DiaMedica Therapeutics began dosing the first two patients in an investigator-sponsored Phase 2 study of DM199 for fetal growth restriction.
• No efficacy results have been presented; the trial will generate future data on whether DM199 can improve fetal growth and prolong pregnancy.
• The open-label, single-arm study will test three dose levels in up to 30 patients with early-onset fetal growth restriction.
• DM199 is designed to boost maternal uterine blood flow to the placenta; the program targets an indication with no approved drug therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260623748526) on June 23, 2026, and is solely responsible for the information contained therein.